-
First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.
Biotech Newswire
May 09, 2024
The first commercial manufacturing run of LYFGENIA – a one-time gene therapy for the treatment of sickle cell disease developed by bluebird bio – was performed at its Allendale, NJ site.
-
MSD, BI and CStone Pharmaceuticals Made Significant Investments in ROR1 ADC
Far-away from the Crowd
May 06, 2024
Ipsen Invested USD 900 Million to Introduce Sutro Biopharma ADC.
-
From Ruxolitinib to Upadacitinib, the USD 5 Billion Blue Ocean Market Ushers a Fierce Battle of JAK Inhibitors
Spuer 203
May 06, 2024
Medical System from Incyte has initiated Phase III clinical trials of vitiligo in China.
-
From CDMO Pharmaceutical Crisaborole First Generic Drug, Look at the Domestic PDE-4 Inhibitor R&D Development Layout
Xiaobin
May 06, 2024
The NMPA official website showed that Zhejiang CDMO Pharmaceutical had submitted an application for the marketing application of crisaborole ointment as a generic drug and it was accepted by the Center for Drug Evaluation.
-
Amidst contentious debates, what path will the FDA take with accelerated approvals?
Krebs Qin
May 06, 2024
Accelerated approval is a privilege that every applicant desires.
-
Oxymetazoline: A Versatile Treatment for Nasal Congestion, Rosacea, and Droopy Eyelid
David Orchard-Webb
May 06, 2024
Oxymetazoline is a derivative of imidazole, which is also a building block of purines in DNA and hormones such as histidine and histamine.
-
ProBioGen Partners with MAPP BIOPHARMACEUTICAL, INC. for Groundbreaking Development of Afucosylated Antibody Against Marburg Virus Disease Using GlymaxX Technology
Biotech Newswire
March 15, 2024
This collaborative effort will leverage ProBioGen's cutting-edge GlymaxX® technology to enhance the therapeutic potential of the antibody by adjusting the afucosylation levels.
-
Drug Apocalypse of the Future: Artificial Intelligence Discovers New Antibiotics, Disrupting Traditional Innovations
Big Cat of Medical Field
March 11, 2024
At present, the use of artificial intelligence to participate in the discovery and design of new drugs has become a hot track for new drug research and development.
-
Pharma Sources Insight January 2024: Pharmaceutical Industry in 2024 - Flexible Production, Innovative Drugs and Personalized Medicine
Pharma Sources Insight
January 15, 2024
Pharmaceutical Industry Outlook in 2024.
-
Global R&D Drug Development 2023: Overcoming Barriers, Bringing Hope to Patients and ESG focused
Shruti Talashi
January 02, 2024
As the global healthcare system refocuses after the pandemic, a recent report on the global R&D trend 2023 which was put together as a public service by the IQVIA Institute for Human Data Science.